Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.51 |
| ▸ | CFTR | P13569 | 5/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695717 | 0.86 | CFTR (0.51) | NOTUMCFTRCES2PDK2SLC6A4 | |
| SCHEMBL18159377 | 0.83 | CYP46A1 (0.53) | NOTUMCFTRCES2SOS1RAB9A | |
| SCHEMBL1995951 | 0.83 | CES2 (0.71) | NOTUMCFTRCES2ALDH1A1HPGD | |
| SCHEMBL24436898 | 0.83 | CA12 (0.61) | NOTUMCFTRCES2PDK2SOS1 | |
| SCHEMBL1671910 | 0.82 | TSHR (0.52) | CES2TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL29891158 | 0.82 | TSHR (0.52) | CES2TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL155135 | 0.81 | NOTUM (0.58) | NOTUMCFTRCES2SLC6A3SOS1 | |
| SCHEMBL30938349 | 0.81 | KDM4E (0.59) | NOTUMCFTRCES2HSD17B10CYP1A2 | |
| SCHEMBL23166545 | 0.81 | NOTUM (0.50) | NOTUMCFTRCES2PDK2SOS1 | |
| SCHEMBL653785 | 0.81 | GAA (0.56) | NOTUMCFTRCES2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3056509-A1 | BOMBESIN ANALOGUES FOR USE IN DIAGNOSIS | Piramal Imaging SA (CH) | 2016-08-17 | — | — | EP | disclosed |
| EP-2455105-B1 | Bombesin analogues | PIRAMAL IMAGING SA (CH) | 2016-02-17 | — | — | EP | disclosed |
| EP-2063918-B1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | PIRAMAL IMAGING SA (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8557776-B2 | Compounds and methods for 18F labeled agents | Bayer Pharma AG (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| EP-2455105-A2 | Bombesin analogues | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20080292548-A1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | Lantheus Biosciences Ltd. (GB) | 2008-11-27 | — | — | US | disclosed |
| EP-1904455-A2 | PYRIDAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008028688-A2 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
| EP-1897885-A1 | Compounds and methods for F labelled agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-12 | — | — | EP | disclosed |
| CN-1922151-A | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA INC (US) | 2007-02-28 | — | — | CN | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | NOTUM 959/4885CFTR 986/4885CES2 590/4885 |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | NOTUM 1763/4885CFTR 145/4885CES2 2784/4885 |
| US-20080292548-A1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | QPCT, GBA2, GBA1 | NOTUM 3355/4885CFTR 3901/4885CES2 174/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | NOTUM 959/4885CFTR 986/4885CES2 590/4885 |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | NOTUM 2418/4885CFTR 2471/4885CES2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.